Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine (CM 57755A)
- PMID: 2906873
- DOI: 10.1007/BF00558249
Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine (CM 57755A)
Abstract
Three groups of eight healthy male volunteers received placebo for 2 days, then daily morning doses either of cimetidine 800 mg, ramixotidine 750 mg (CM 57755A), or placebo, for 14 days, and then were all returned to placebo for one more day. Plasma levels of prolactin, testosterone and 17 beta-estradiol were measured on Days 2, 3, 16 and 17 in blood samples taken 30 and 15 min before and 0, 60, 120, 180, 240 and 300 min after treatment. Gastrin was assayed in blood collected on the same days 180 min after treatment. Mean pre- and post-treatment areas under the time-concentration curves of the first three hormones were not significantly different in the three groups on any test day, or within the same group throughout the four test days. Mean plasma gastrin levels ranged between 27 and 42 pg/ml, respectively, in the placebo and cimetidine treated groups on test day 3, and intermediate values were found in the group receiving CM 57755A. There was no statistically significant difference in gastrin level between the groups on any test day or within the same group throughout the four test days. No subjective side-effects attributable to the treatments were reported, and there were no abnormalities in blood pressure, heart rate or standard laboratory tests.
Similar articles
-
Comparison of the gastric antisecretory effects of ramixotidine dihydrochloride (CM 57755), a new H2 receptor antagonist, and cimetidine in dogs.Pharmacol Res Commun. 1988 Aug;20(8):663-72. doi: 10.1016/s0031-6989(88)80113-9. Pharmacol Res Commun. 1988. PMID: 2974998
-
Inhibition of pentagastrin-stimulated gastric acid secretion and plasma levels of the new histamine H2-receptor antagonist ramixotidine dihydrochloride (CM 57755) in human volunteers.Eur J Clin Pharmacol. 1987;32(5):467-70. doi: 10.1007/BF00637671. Eur J Clin Pharmacol. 1987. PMID: 2957210 Clinical Trial.
-
Comparative study of plasma gastrin levels in rats after two months of ebrotidine administration.Arzneimittelforschung. 1997 Apr;47(4A):524-7. Arzneimittelforschung. 1997. PMID: 9205757
-
Effects of cimetidine and ranitidine on gastric transmural potential difference and on prolactin secretion in man.Hepatogastroenterology. 1981 Aug;28(4):210-2. Hepatogastroenterology. 1981. PMID: 6115806
-
Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.Clin Pharmacokinet. 1991 Mar;20(3):218-36. doi: 10.2165/00003088-199120030-00004. Clin Pharmacokinet. 1991. PMID: 1673880 Review.
Cited by
-
Safety of acid-suppressing drugs.Dig Dis Sci. 1995 Feb;40(2 Suppl):63S-80S. doi: 10.1007/BF02214872. Dig Dis Sci. 1995. PMID: 7859585 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical